📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Lotus Eye Hospital Cancels Voluntary Delisting Proposal from NSE
Lotus Eye Hospital and Institute Limited has decided to withdraw its proposal for voluntary delisting from the National Stock Exchange (NSE). The Board of Directors, in their meeting on March 17, 2026, cited current market conditions and the necessity of maintaining liquidity for investors as key reasons for this decision. Consequently, the company's equity shares will continue to be listed and traded on both the BSE and NSE. This reversal ensures that shareholders retain maximum flexibility and convenience for trading their holdings.
Key Highlights
Board decided not to proceed with the voluntary delisting of equity shares from the NSE
Company will maintain its dual listing status on both BSE Limited and NSE
Decision influenced by current market conditions and the need to ensure investor liquidity
Board meeting concluded at 5:00 PM on March 17, 2026
💼 Action for Investors
Investors should view this as a positive development as it preserves liquidity and price discovery across both major exchanges. No action is required as the company will remain publicly traded on both the NSE and BSE.
Lotus Eye Hospital Reports Q3 FY26 Net Loss of ₹26 Lakhs; Appoints New Company Secretary
Lotus Eye Hospital and Institute Limited reported a net loss of ₹26.07 lakhs for the quarter ended December 31, 2025, a decline from a profit of ₹11.58 lakhs in the preceding quarter. While revenue from operations grew 10.6% year-on-year to ₹1,354.96 lakhs, total expenses rose significantly to ₹1,416.07 lakhs, leading to the loss. For the nine-month period ended December 2025, the company's net profit stands at ₹39.99 lakhs, down from ₹48.69 lakhs in the previous year. The board also appointed Mr. Prathish S as the new Company Secretary and Compliance Officer.
Key Highlights
Revenue from operations increased 10.6% YoY to ₹1,354.96 lakhs in Q3 FY26.
Reported a net loss of ₹26.07 lakhs for the quarter compared to a profit of ₹11.58 lakhs in Q2 FY26.
Total expenses rose to ₹1,416.07 lakhs, driven by higher service expenses of ₹276.74 lakhs and employee benefits of ₹313.76 lakhs.
Nine-month net profit declined to ₹39.99 lakhs from ₹48.69 lakhs in the previous year's corresponding period.
Appointment of Mr. Prathish S as Company Secretary & Compliance Officer effective February 13, 2026.
💼 Action for Investors
Investors should be cautious as rising operational and employee costs are eroding margins despite steady revenue growth. Monitor the company's cost-management strategies in upcoming quarters to see if they can return to consistent profitability.
Lotus Eye Hospital Q3 FY26 Revenue up 10.6% YoY to ₹13.55 Cr; Swings to Net Loss
Lotus Eye Hospital and Institute Limited reported a 10.6% year-on-year growth in revenue from operations to ₹1,354.96 lakhs for the quarter ended December 31, 2025. Despite the revenue growth, the company reported a net loss of ₹26.07 lakhs for the quarter, compared to a profit of ₹11.58 lakhs in the preceding quarter. Total expenses rose to ₹1,416.07 lakhs, driven by increased service and employee benefit costs. For the nine-month period ended December 2025, net profit declined by 17.9% to ₹39.99 lakhs compared to the previous year.
Key Highlights
Revenue from operations increased 10.6% YoY to ₹1,354.96 lakhs from ₹1,224.69 lakhs.
Reported a net loss of ₹26.07 lakhs in Q3 FY26 versus a profit of ₹11.58 lakhs in Q2 FY26.
Total expenses for the quarter rose to ₹1,416.07 lakhs, exceeding total income of ₹1,378.51 lakhs.
Nine-month net profit decreased to ₹39.99 lakhs from ₹48.69 lakhs in the corresponding period last year.
Appointed Mr. Prathish S as Company Secretary & Compliance Officer effective February 13, 2026.
💼 Action for Investors
Investors should monitor the company's rising operational expenses, which have pushed the bottom line into the red despite steady revenue growth. The stock may face short-term pressure due to the quarterly loss and declining nine-month profitability.